Septerna (SEPN) Names A New CMO, Is The Upside Already Priced In?

Septerna (SEPN) has drawn fresh investor attention after appointing Rajiv Patni, M.D., as Chief Medical Officer. The move raises new questions about how his track record in drug development could influence the company’s clinical priorities and risk profile.

Septerna’s latest executive change comes after a strong run in the stock, with the share price at US$38.91 and a year to date share price return of 39.06%, alongside a very large 1 year total shareholder return of 221.57%.

Spot momentum in Septerna, then scan for other clinical and biotech stocks showing similar strength using the hand picked 19 high quality undiscovered gems.

After that kind of run, the key issue is whether Septerna’s recent momentum and new CMO appointment still leave meaningful upside on the table, or if investors have already captured most of the opportunity as valuation tightens.

Preferred Price-to-Sales Multiple of 18.4x: Is it justified?

With Septerna’s share price at $38.91 and a very large 1 year total shareholder return, the valuation question now sits squarely on its P/S multiple. The stock is described as expensive on a price-to-sales basis, which matters for a clinical-stage biotech that is still unprofitable.

The price-to-sales, or P/S, ratio compares the company’s market value to its revenue. For Septerna, that ratio currently sits at 18.4x according to the assessment provided. This is often used for early stage or loss-making biotechs where earnings are not yet a useful anchor, since investors are effectively paying for current revenue plus expectations around the pipeline.

Here the comparison with peers is stark. The P/S of 18.4x is much higher than both the US Pharmaceuticals industry average of 5.1x and the peer group average of 8x. It is also described as high relative to an estimated fair P/S ratio of 3.4x. This is the level the market could potentially move toward if sentiment or expectations around Septerna’s prospects were to cool.

Explore the SWS fair ratio for Septerna.

Result: Price-to-Sales of 18.4x (OVERVALUED)

However, Septerna’s unprofitable status and annual declines in both revenue and net income growth leave the stock exposed if clinical timelines slip or partnership activity disappoints.

Find out about the key risks to this Septerna narrative.

Next Steps

Given the mixed sentiment around Septerna’s rapid share price move and rich P/S ratio, it makes sense to review the underlying data quickly and decide whether the current risk reward profile fits your approach by starting with the 1 key reward and 2 important warning signs.

Looking for more investment ideas beyond Septerna?

If Septerna’s story has your attention, do not stop here. Broaden your watchlist now so you are not relying on a single opportunity.

• Target bargain opportunities by scanning a curated 45 high quality undervalued stocks that pairs strong fundamentals with prices that may not fully reflect them.
• Strengthen your income focus by reviewing a hand picked 12 dividend fortresses offering higher yields with an emphasis on resilience.
• Protect your downside by assessing a carefully filtered 75 resilient stocks with low risk scores chosen for more stable financial and risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com